Skip to main content

Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors


Panitumumab is a fully human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting the growth and survival of tumors expressing EGFR. Panitumumab received approval in the USA in 2006 for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer. Over the last 10 years, the pharmacokinetic and pharmacodynamic profile of panitumumab has been studied to further evaluate its safety, efficacy, and optimal dosing regimen. In this review, we summarize the key clinical pharmacokinetic and pharmacology data for panitumumab, and considerations for its use in special populations. Panitumumab has a nonlinear pharmacokinetic profile and its approved dosing regimen (6 mg/kg every 2 weeks) is based on body weight; dose adjustments are not needed based on sex, age, or renal or hepatic impairment. Drug interactions do not occur when panitumumab is combined with chemotherapy drugs including irinotecan, paclitaxel, and carboplatin. The level of tumor EGFR expression was found to have no effect on panitumumab pharmacokinetics or efficacy. The incidence of anti-panitumumab antibodies is low; when anti-panitumumab antibodies are produced, they do not affect the efficacy, safety, or pharmacokinetics of panitumumab. In summary, the pharmacokinetic and pharmacodynamic profile of panitumumab is well suited for standard dosing, and the approved body weight–based dosing regimen maintains efficacy and safety in the treatment of wild-type RAS metastatic colorectal cancer across a broad range of patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. Vectibix® (panitumumab). Full prescribing information. Amgen Inc., Thousand Oaks, CA, 2017.

  2. Vectibix (panitumumab). Summary of product characteristics. Amgen Europe B.V., Breda, Netherlands, 2018.

  3. Battaglin F, Puccini A, Ahcene Djaballah S, et al. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. Cancer Manag Res. 2019;11:5911–24.

    CAS  Article  Google Scholar 

  4. Hendrikx J, Haanen J, Voest EE, et al. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212–21.

    CAS  Article  Google Scholar 

  5. Hendrikx JJMA, Beijnen JH, Huitema ADR. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Letter]. Clin Pharmacol Adv Appl. 2020;12:177–8.

    Google Scholar 

  6. Liao MZ, Berkhout M, Prenen H, et al. Dose regimen rationale for panitumumab in cancer patients: to be based on body weight or not. Clin Pharmacol. 2020;12:109–14.

    PubMed  PubMed Central  Google Scholar 

  7. Mitchell RA, Luwor RB, Burgess AW. Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics. Exp Cell Res. 2018;371(1):1–19.

    CAS  Article  Google Scholar 

  8. Koveitypour Z, Panahi F, Vakilian M, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9:97.

    Article  Google Scholar 

  9. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.

    CAS  Article  Google Scholar 

  10. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59(6):1236–43.

    CAS  PubMed  Google Scholar 

  11. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38(1):17–23.

    CAS  Article  Google Scholar 

  12. Voigt M, Braig F, Gothel M, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia. 2012;14(11):1023–31.

    CAS  Article  Google Scholar 

  13. Center for Drug Evaluation and Research. Vectibix® (Panitumumab), application number 125147/0 (Clinical Pharmacology and Biopharmaceutics Review). 2006. Accessed 1 Nov 2020.

  14. Freeman DJ, Bush T, Ogbagabriel S, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther. 2009;8(6):1536–46.

    CAS  Article  Google Scholar 

  15. Freeman DJ, McDorman K, Ogbagabriel S, et al. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer. 2012;11:47.

    CAS  Article  Google Scholar 

  16. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184(1):512–20.

    CAS  Article  Google Scholar 

  17. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1277–81.

    Article  Google Scholar 

  18. Ma P, Yang BB, Wang YM, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009;49(10):1142–56.

    CAS  Article  Google Scholar 

  19. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22(15):3003–15.

    CAS  Article  Google Scholar 

  20. Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008;14(2):502–8.

    CAS  Article  Google Scholar 

  21. Yang BB, Lum P, Chen A, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 2010;49(11):729–40.

    CAS  Article  Google Scholar 

  22. Krens LL, Baas JM, Guchelaar HJ, et al. Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. Cancer Chemother Pharmacol. 2018;81(1):179–82.

    CAS  Article  Google Scholar 

  23. Krens LL, Baas JM, de Jong FA, et al. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemother Pharmacol. 2014;73(2):429–33.

    CAS  Article  Google Scholar 

  24. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–72.

    CAS  Article  Google Scholar 

  25. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6(6):427–32.

    CAS  Article  Google Scholar 

  26. Yang BB, Wu CY, Chen E, et al. Pharmacokinetics of irinotecan with and without panitumumab coadministration in patients with metastatic colorectal cancer. Clin Pharmacol Drug Dev. 2013;2(3):205–12.

    CAS  Article  Google Scholar 

  27. Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Eur J Cancer Suppl. 2005;3(2):324.

    Google Scholar 

  28. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110(5):980–8.

    CAS  Article  Google Scholar 

  29. Ketzer S, Schimmel K, Koopman M, et al. Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer. Clin Pharmacokinet. 2018;57(4):455–73.

    CAS  Article  Google Scholar 

  30. Hendrikx J, Beijnen JH, Huitema ADR. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Letter]. Clin Pharmacol. 2020;12:177–8.

    PubMed  PubMed Central  Google Scholar 

  31. Liao MZ, Kast J, Berkhout M, et al. Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Response to letter]. Clin Pharmacol Adv Appl. 2020;12:189–90.

    Google Scholar 

  32. European Medicines Evaluation Agency. Vectibix: scientific discussion. Amsterdam, the Netherlands: European Medicines Agency; 2007. Accessed 21 Dec 2020.

  33. Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J Clin Oncol. 2007;25(18_suppl):4082.

    Article  Google Scholar 

  34. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009;39(5):321–6.

    Article  Google Scholar 

  35. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64.

    Article  Google Scholar 

  36. Crawford J, Swanson P, Schwarzenberger P, et al. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1510–8.

    CAS  Article  Google Scholar 

  37. Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 2007;13(16):4664–6.

    CAS  Article  Google Scholar 

  38. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1–9.

    CAS  Article  Google Scholar 

  39. Lofgren JA, Dhandapani S, Pennucci JJ, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol. 2007;178(11):7467–72.

    CAS  Article  Google Scholar 

  40. Weeraratne D, Chen A, Pennucci JJ, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011;11:17.

    CAS  Article  Google Scholar 

Download references



Amgen Inc. funded this analysis and the journal’s Rapid Service fees.

Medical Writing/Editorial Assistance

The authors thank Lee Hohaia, PharmD, and Allison Gillies, PhD (ICON, North Wales, PA), whose work was funded by Amgen Inc., for medical writing assistance in the preparation of this manuscript.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authors’ Contributions

All authors contributed equally to this manuscript’s conception, design, material preparation, data collection and analysis, reviewed and edited the manuscript, and read and approved the final manuscript.

Prior Presentation

Although based on previously conducted studies, the analyses in this article have not been presented or published previously.


Johannes Kast, Sandeep Dutta and Vijay V. Upreti are employees of and stockholders in Amgen Inc.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data Availability

Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following:

Author information

Authors and Affiliations


Corresponding author

Correspondence to Vijay V. Upreti.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kast, J., Dutta, S. & Upreti, V.V. Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors. Adv Ther 38, 3712–3723 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Clinical pharmacology
  • Colorectal neoplasms
  • Dose–exposure relationship
  • Epidermal growth factor receptor antagonist
  • Panitumumab
  • Pharmacokinetics